Skip to content
AnalystLens

Medline Inc. 8-K Report, Regulation FD Disclosure (Oct 21, 2026)

Reports
Regulation FD
Filing Date
Filed October 21, 2026
Period End
October 21, 2026
Security
MDLN
In the record · 2025–202610-K110-Q28-K9

MDLN filed 1 annual reports (10-K), 2 quarterly reports (10-Q) and 9 current reports (8-K) between 2025 and 2026.

  1. Leadership change8-K · Dec ’25Dec ’25
  2. Leadership change8-K · Jul ’26Jul ’26

01—Abstract

Summary

Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.

Medline Inc. (MDLN) has announced a voluntary field action involving the discontinuation and market exit of all Medline Brand beds, including homecare, bariatric, and long-term care beds, along with associated accessories.

This strategic move impacts the Front Line Care product category within the Medline Brand segment. The company reported that the affected products generated approximately $60 milliona in net sales for the twelve months ended June 27, 2026. Medline currently estimates the total costs associated with this action, including product discontinuation, inventory impairment, disposal costs, and customer credits, to be up to $220 million.

These costs are anticipated to be recognized in fiscal years 2026 and 2027 and will be excluded from Adjusted EBITDA. Despite these significant costs, Medline does not expect this action to materially impact its full-year 2026 financial results or its previously issued guidance.

02—Key points

Key Highlights

  1. Voluntary discontinuation and market exit of all Medline Brand beds and related accessories.
  2. Affected products contributed approximately $60 million in net sales for the twelve months ended June 27, 2026.
  3. Estimated costs associated with the field action are up to $220 million.
  4. Costs expected to be incurred in fiscal years 2026 and 2027.
  5. Costs will be excluded from Adjusted EBITDA calculations.
  6. Company does not anticipate a material impact on fiscal year 2026 financial results or guidance.
  7. Additional information is available on Medline's corporate website.

03—Questions

Frequently Asked Questions

  1. What is the nature of the voluntary field action Medline Inc. is undertaking?

    Medline Inc. is voluntarily discontinuing and exiting the market for all Medline Brand beds, including homecare, bariatric, and long-term care beds, as well as their associated pendants, accessories, replacement parts, and bed-containing order packages. This affects the Front Line Care product category within the Medline Brand segment.

  2. What is the financial impact of this action on Medline Inc.?

    The company estimates costs of up to $220 million related to product discontinuation, inventory impairment, disposal, and customer credits. These costs are expected to be incurred in 2026 and 2027 and will be excluded from Adjusted EBITDA. Despite these costs, Medline does not expect a material impact on its 2026 financial results or its previously issued guidance.

  3. How much revenue did the affected products generate?

    The net sales of the affected Medline Brand beds and associated products were approximately $60 million for the twelve months ended June 27, 2026.

  4. When are the costs associated with this field action expected to be recognized?

    The company expects to incur these costs primarily in fiscal years 2026 and 2027.

04—Continue

← View all 8-K filings